French pharmaceutical company Servier signed a scientific partnership with Poietis, a to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. The final goal is to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. Hepatotoxic potential is poorly detected by current preclinical models and, while such lesions are rare, they can have serious consequences for patients. Current models based on human cell cultures often lack longevity and complexity, which limits their usefulness in toxicology. Poietis’s technology allows the reproduction of a new, complex, 4D bioprinted human liver tissue containing lines of human liver cells and immunocompetent cells within a defined architecture designed to imitate human liver tissue in vitro.

LEAVE A REPLY

Please enter your comment!
Please enter your name here